Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Long-Term Outcomes for Lumbar Spinal Stenosis Patients Treated With X STOP®

This study has been completed.
Information provided by (Responsible Party):
Medtronic Spine LLC Identifier:
First received: September 20, 2007
Last updated: February 16, 2012
Last verified: July 2011

The Long-Term Outcomes Study (LTOS) is a multi-center longitudinal cohort study of all patients who received the X-STOP device in the Pivotal Trial, Continued Access Protocol (CAP), or Cross-over Study (COS). It is designed to supplement postmarket safety and effectiveness data to be gathered in a Condition of Approval (CoA) study of a population of patients with moderately impaired physical function who elect to undergo X-STOP surgery.

Condition Intervention Phase
Lumbar Spinal Stenosis
Device: X STOP® Interspinous Process Decompression System
Phase 4

Study Type: Observational
Study Design: Observational Model: Cohort
Official Title: Long-term Outcomes Among Patients With Lumbar Spinal Stenosis Treated With the X STOP® Interspinous Process Decompression System: Five-Year Follow-up of IDE Patient Cohorts

Resource links provided by NLM:

Further study details as provided by Medtronic Spine LLC:

Primary Outcome Measures:
  • Number of Patient Successes Based on Treatment Response for Target Population [ Time Frame: 3+ years following first 2 years post-X-STOP implant through IDE study ] [ Designated as safety issue: Yes ]
    Treatment response defined by 7 separate criteria as follows: Clinically significant improvement (at least 0.5 points) in Symptom Severity domain of Zurich Claudication Questionnaire (ZCQ), clinically significant improvement (at least 0.5 points) in Physical Function domain of ZCQ, Patient Satisfaction score of <2.5 points in ZCQ, no additional lumbar spinal stenosis surgery, maintenance of distraction, no device dislodgement, no device-related complications. All 7 criteria must be met to be considered a treatment success.

Secondary Outcome Measures:
  • Secondary Measures of Long-term Effectiveness Include the Following: ZCQ Domain Scores and SF-36 Scores. Proportions Will be Analyzed for the Primary Efficacy Assessment. For Continuous Variables, Means and Standard Deviations Will be Presented. [ Time Frame: Five years ] [ Designated as safety issue: No ]

Enrollment: 69
Study Start Date: December 2006
Study Completion Date: June 2010
Intervention Details:
    Device: X STOP® Interspinous Process Decompression System
    The X STOP is a titanium implant that fits between the spinous processes of the lumbar spine. It is made from Ti-6AI-4V Eli titanium alloy (ISO 5832/3) and consists of two components: a spacer assembly and a wing assembly.
Detailed Description:

Evaluate the long term safety and effectiveness of the X-Stop interspinous process decompression system In the patients who received the X-Stop under the IDE. These patients consist of two cohorts to be evaluated: patients who had moderately impaired physical function prior to X-Stop implantation (as determined by a baseline score >2.0 in the physical function (PF) domain of the Zurich claudication questionnaire), and patients who had mildly impaired physical function prior to X-Stop surgery(as determined by a baseline score <=2.0 in the PF domain of the Zurich claudication questionnaire (ZCQ), through the fifth postoperative year. Clinical examination will be performed at each office visit to confirm the absence of neurological complications. X-ray films (AP/lateral views) taken during the fifth postoperative year will, be analyzed to confirm A) maintenance of distraction and B) the absence of radiological evidence of device-related complications. Secondary endpoints will include mean scores from the SF-36, and incidence rates of adverse events, device failures, and secondary surgeries.


Ages Eligible for Study:   50 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Patients who received implants and completed participation in the Pivotal, CAP, or COS studies and has the implant intact and is willing and able to provide consent and return to the clinic for evaluation or complete study questionnaires.


Inclusion Criteria:

A patient will be admitted into the LTOS program if he/she meets all of the following inclusion criteria:

  1. Completed participation in the Pivotal Trial, CAP, or COS and has the X STOP implant(s) intact at the time of LTOS enrollment; OR is an active CAP/COS participant, has the X STOP implant(s) intact, and has not completed a 24-month follow-up visit in his/her CAP/COS study.
  2. Is willing and able to provide Informed Consent
  3. Is willing and able to return to the clinic for a clinical evaluation or complete study questionnaires without a clinic visit.

Exclusion Criteria:

A patient will not be admitted into the LTOS program if he/she meets any of the following exclusion criteria:

  1. Participated in the Pivotal Trial as part of the X STOP group, but the device has been removed.
  2. Participated in the CAP or COS programs, but the device has been removed.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00534092

United States, California
St. Mary's Spine Center
San Francisco, California, United States, 94117
United States, Maine
Neurological & Spine Associates
Scarborough, Maine, United States, 04074
United States, Maryland
Greater Baltimore Spine Care
Timonium, Maryland, United States, 21093
United States, Virginia
Neurological Specialist
Norfolk, Virginia, United States, 23510
United States, Wisconsin
University Hospital
Madison, Wisconsin, United States, 53792
Sponsors and Collaborators
Medtronic Spine LLC
  More Information

Responsible Party: Medtronic Spine LLC Identifier: NCT00534092     History of Changes
Other Study ID Numbers: LSS-004-LTO
Study First Received: September 20, 2007
Results First Received: June 2, 2011
Last Updated: February 16, 2012
Health Authority: United States: Institutional Review Board

Keywords provided by Medtronic Spine LLC:
Lumbar Spinal Stenosis

Additional relevant MeSH terms:
Constriction, Pathologic
Spinal Stenosis
Bone Diseases
Musculoskeletal Diseases
Pathological Conditions, Anatomical
Spinal Diseases processed this record on March 01, 2015